ENZYME TAGGING OF MALIGNANT CERVICAL EPITHELIAL CELLS

该项目的长期目标是开发一种自动化的 PAP筛查仪器（试剂与仪器集成） 污迹 第一阶段将用于证明使用2 针对2种酶的单克隆抗体作为系统中的关键试剂。 简单地说，PAP涂片将被允许与两个单克隆抗体相互作用。 每个抗体携带独特的荧光报告分子。 这些抗体已被选择用于鉴定和定量乳酸 脱氢酶（LD）和腺苷酸环化酶（AC）。 LD发生在 高于正常，AC在肿瘤细胞中处于低至正常浓度。 一种能够同时阅读两个离散波长的荧光计， 因此，可以制定一个数字比率，这将评估程度， 在给定的幻灯片中表示了哪种瘤形成。 基于这些比率， 正常载玻片（所有载玻片的85-90%）将不需要进一步评价， 只有异常切片，将不需要由细胞技术/细胞学家读取。

The long term aim of this project is the development of an automated screening instrument (reagents integrated with instrumentation) for PAP smears. Phase I will be used to demonstrate the feasibility of using 2 monoclonal antibodies against 2 enzymes as the key reagents in the system. Briefly the PAP smear will be allowed to interact with two monoclonal antibodies each carrying a distinctive fluorescent reporter molecular. These antibodies have been selected to identify and quantitate lactated dehydrogenase (LD) and adenyl cyclase (A C) respectively. LD occurs in higher than normal, AC in low to normal concentrations in neoplastic cells. A fluorometer capable of reading two discreet wavelengths simultaneously, can therefore develop a numerical ratio, which will assess the degree to which neoplasia is represented in a given slide. Based on these ratios, normal slides (85-90% of all the slides) will need no further evaluation, abnormal slides only, will need t be read by the cytotech/cytologist.